Skip to main content
DongKoo Bio & Pharma Co., Ltd. logo

DongKoo Bio & Pharma Co., Ltd. — Investor Relations & Filings

Ticker · 006620 ISIN · KR7006620009 KO Manufacturing
Open in API
Filings indexed 212 across all filing types
Latest filing 2022-04-14 Major Shareholding Noti…
Country KR South Korea
Listing KO 006620

About DongKoo Bio & Pharma Co., Ltd.

https://www.dongkoo.com/eng/

DongKoo Bio & Pharma Co., Ltd. is a biopharmaceutical company that manufactures and sells a range of pharmaceuticals and health supplements. The company holds a leading position in the dermatology prescription market, with a product portfolio that includes antihistamines, analgesics, antipyretics, and digestants. Strategically expanding beyond traditional pharmaceuticals, DongKoo Bio & Pharma is focused on the biotechnology sector, particularly the development of stem cell-based therapies. This growth is pursued through an "Open Innovation" model to build a pipeline of differentiated products, supported by its research centers and PIC/s compliant GMP manufacturing facilities.

Recent filings

Filing Released Lang Actions
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding), which is a standard regulatory filing in South Korea under the Capital Markets Act. It details changes in share ownership, specifically regarding collateral agreements (담보계약 변경) by the major shareholder and related parties of Dongkoo Bio & Pharma. This falls under the category of Major Shareholding Notification.
2022-04-14 Korean
주요사항보고서(자기주식취득신탁계약해지결정)
Transaction in Own Shares Classification · 100% confidence The document is a 'Major Report' (주요사항보고서) filed with the Korean financial authorities regarding the termination of a trust agreement for the acquisition of treasury shares (자기주식취득 신탁계약 해지 결정). This falls under the category of company share buyback or treasury share management activities. According to the provided definitions, 'Transaction in Own Shares' (POS) is the correct classification for reports concerning the company buying back or selling its own shares.
2022-04-13 Korean
신탁계약해지결과보고서
Transaction in Own Shares Classification · 100% confidence The document is a '신탁계약해지결과보고서' (Report on the Termination of a Trust Agreement) filed by Dongkoo Bio & Pharma Co., Ltd. to the Financial Supervisory Service (FSS) in South Korea. It details the termination of a trust agreement for the acquisition of treasury shares and the subsequent transfer of those shares to the company's own account. This type of filing is a standard regulatory disclosure regarding treasury share transactions and capital structure changes, which falls under the 'Transaction in Own Shares' category.
2022-04-13 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding), which is a standard regulatory filing in South Korea under the Capital Markets Act. It details the shareholding status of major shareholders and their special related parties, including changes in ownership due to the appointment of new executives. This falls under the category of 'Major Shareholding Notification' (MRQ).
2022-04-05 Korean
정기주주총회결과
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is an official report of the results from a General Meeting of Shareholders (Annual General Meeting). It details the outcomes of voting on agenda items such as financial statement approval, dividend declarations, and the election of directors. This aligns perfectly with the definition for 'Declaration of Voting Results & Voting Rights Announcements'.
2022-03-29 Korean
감사보고서제출
Audit Report / Information Classification · 100% confidence The document is a formal announcement titled '감사보고서 제출' (Submission of Audit Report) filed by Dongkoo Bio & Pharma. It provides a summary of the audit opinion (which is 'unqualified' or '적정') and key financial data (assets, liabilities, revenue, net income) for the fiscal year. According to the 'Menu vs Meal' rule, this is a short regulatory announcement notifying the market that the audit report has been submitted, rather than the full, lengthy audit report document itself. Therefore, it is classified as a Report Publication Announcement (RPA). FY 2021
2022-03-21 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.